Diagnostic and Prognostic Value of MicroRNAs in Metastasis and Recurrence of Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis

Ke Qiu†, Yao Song†, Yufang Rao†, Qiurui Liu1, Danni Cheng1, Wendu Pang1, Jianjun Ren1,2,3* and Yu Zhao1*

1 Department of Oto-Rhino-Laryngology, West China Hospital, Sichuan University, Chengdu, China, 2 West China Biomedical Big Data Center, West China Hospital/West China School of Medicine, Sichuan University, Chengdu, China, 3 Medical Big Data Center, Sichuan University, Chengdu, China

MicroRNAs have been proven to make remarkable differences in the clinical behaviors of head and neck squamous cell carcinoma (HNSCC). This study aims to systematically analyze whether differential expression levels of microRNAs are related to recurrence or metastasis in patients with HNSCC. A comprehensive search of the PubMed, EMBASE, and CENTRAL was conducted up to July 24th, 2021. Data were collected and combined from studies reporting recurrence-free survival (RFS) of HNSCC patients with high microRNA expression compared to those with low expression. Besides, studies providing necessary data for evaluating the diagnostic value of microRNAs for detecting recurrence and metastasis based on their expression levels were also included and combined. The pooled hazard ratio (HR) value for the outcomes of RFS in 1,093 HNSCC samples from 10 studies was 2.51 (95%CI: 2.13–2.96). A sensitivity of 0.79 (95% CI: 0.72–0.85) and specificity of 0.77 (95%CI: 0.68–0.83) were observed in three studies, of which 93 patients with recurrence and 82 nonrecurrence controls were included, and the area under the curve (AUC) was 0.85 (95% CI: 0.81–0.88). Additionally, high diagnostic accuracy of microRNAs in detecting lymph node metastasis (LNM) was also reported. In conclusion, two panels of microRNAs showed the potential to predict recurrence or diagnose recurrence in HNSCC patients, respectively, which could facilitate prognosis prediction and diagnosis of clinical behaviors in HNSCC patients.

Systematic Review Registration: PROSPERO (https://www.crd.york.ac.uk/prospero), identifier CRD42020161117.

Keywords: microRNA, head and neck squamous cell carcinoma (HNSCC), recurrence-free survival (RFS), metastasis, diagnostic accuracy, meta-analysis
INTRODUCTION

Head and neck squamous cell carcinomas (HNSCCs), visualized as the most common form of human solid tumors in the head and neck region, account for a large proportion of cancer mortality worldwide (1, 2). A multiple process that accumulates genetic mutations sequentially is believed to play a critical role in the formation of HNSCCs. And these highly heterogeneous tumors are derived from stratified epithelial cells of various anatomical subsites, mainly including the oral cavity, tongue, nasal cavity, larynx, and pharynx (3, 4). However, recent studies had illustrated similarities in genomic, genetic, and epigenetic alterations between HNSCCs from different subsites, which suggested the existence of certain common mechanisms underlying the initiation and progression of HNSCCs (3, 5, 6). It is estimated that approximately 1/3 of HNSCC patients develop recurrence or metastasis after receiving standard therapies, and the majority of them ended with poor prognosis (7, 8). Currently, tumor-node-metastasis (TNM) staging based on imaging modalities and biopsy represents the leading way to predict HNSCCs’ biological behaviors, especially for metastasis and recurrence; however, accuracy varied among HNSCCs with different origins (9, 10). Therefore, reliable and detectable biomarkers may contribute to the diagnosis and prediction of metastasis and recurrence of SCCs.

MicroRNAs, a special class of noncoding RNAs (19–23 nucleotides in length), are capable of binding to their target mRNAs and regulating gene expression at the post-transcriptional level (11). In the past decade, microRNAs had been proven to make remarkable differences in HNSCC carcinogenesis and cancer progression, making them potential biomarkers to predict biological behaviors of HNSCCs (12–18). This meta-analysis aimed at evaluating the diagnostic and prognostic values of microRNAs in the recurrence and metastasis of human SCCs.

METHODS AND MATERIALS

Protocol and Eligibility Criteria

This study was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines (19) and was already registered on prospero (registration number: CRD42020161117).

The inclusion criteria were as follows: 1) studies written in English; 2) the diagnosis of HNSCC was confirmed by histopathology; 3) studies demonstrating the expression levels of microRNA by quantitative polymerase chain reaction (qPCR), in situ hybridization (ISH), fluorescent in situ hybridization (FISH), or RNA sequencing; 4) studies reporting HR with 95% confidence interval (CI) or Kaplan–Meier curves related to the correlation of microRNA expression with RFS; and 5) studies providing necessary data for evaluating the diagnostic value of microRNAs in predicting recurrence and metastasis.

The exclusion criteria were as follows: 1) studies related to nonhuman samples; 2) studies providing combined outcomes of more than one microRNA or insufficient data; 3) duplicate studies; 4) studies in the form of reviews, letters, editorials, meeting abstracts, or case reports; and 5) studies reporting SCC not originated from the head and neck region.

More specifically, for the meta-analysis evaluating the predictive values of microRNAs, we aimed to address the question of whether HNSCC patients with a higher expression level of microRNAs had different risk of cancer recurrence compared to HNSCC patients with a lower expression level of microRNAs. And for the meta-analysis evaluating the diagnostic values of microRNAs, we aimed to address the question of whether the expression level of microRNAs in human biospecimen could be used as indicators for distinguishing the HNSCC patients with recurrence/metastasis or not.

Information Sources and Search Strategies

A comprehensive search of the PubMed, EMBASE, and CENTRAL was conducted from the beginning of each database to July 24th, 2021. Meanwhile, additional records from other sources, e.g., the references of included studies and original studies mentioned in reviews, were also screened.

A Boolean combination of Mesh terms and free text words were used as search strategies, mainly including “Carcinoma, Squamous Cell”[Mesh], “MicroRNA”, “MiRNAs”, “MicroRNAs”[Mesh], “Metastasis”, “Metastases”, “Recurrences”, “Relapse”, and “Recurrence”[Mesh]. Detailed search strategies were presented in Supplementary Material.

Study Selection, Data Collection Process, and Data Items

The initial screening of titles and abstracts were conducted independently by two authors, and full texts would be reviewed if the titles and abstracts were ambiguous. Any discrepancy was solved by consensus, and a third author would participate if necessary. Finally, studies fulfilling all inclusion criteria were included in the systematic review.

Data extraction for studies investigating the RFS and diagnostic value was also independently performed and cross-checked by two authors. The agreement between authors KQ and YS was determined by Cohen’s kappa score. And the extracted items were as follows: year of publication, first author, country, microRNAs studied, type of microRNA dysregulation, sample sizes, duration of follow-up, tumor sites, metastasis sites, detection assay, sample types, and cutoffs for the expression of microRNAs.

Risk of Bias Assessment, Summary Measures, and Statistical Analyses

The risk of bias within each included prognostic study was evaluated by the Newcastle-Ottawa Scale (NOS) (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp), and the risk of bias within each included diagnostic study was evaluated by the tool provided by Quality Assessment of Diagnostic Accuracy Studies—2 (QUADAS-2) (20), while the risk of bias across studies was evaluated by the Cochran Q test.
and Higgins index ($I^2$). Heterogeneity was considered significant if $P < 0.05$ in Q test, and subgroup analyses were applied to find the potential sources of heterogeneity. Besides, overall effects were analyzed by a fixed-effect model if $I^2 < 50$%; otherwise, a random-effects model would be applied.

For studies investigating RFS, ln[HR] and standard error (SE) were synthesized (21). The publication bias was tested by Begg’s test. For studies investigating diagnostic values, we calculated the pooled sensitivity and specificity. The summary receiver operator characteristic (SROC) curve and the area under the SROC curve (AUC) were constructed and calculated to explore the diagnostic accuracy of microRNAs in metastasis/recurrence. Additionally, the publication bias was tested by Deek’s funnel plot asymmetry test.

The STATA 12.0 (Stata Corp, College Station, TX, USA) and Review Manager (Version 5.4, The Cochrane Collaboration, 2020) software was used for all meta-analysis, and $P < 0.05$ was considered significant.

RESULTS

Study Selection
A total of 3,349 records were retrieved through the initial comprehensive search. A total of 1,860 articles remained after excluding duplicates and were screened according to titles and abstracts. Subsequently, 398 studies remained and underwent full-text screening. A total of 14 studies that fully met the inclusion criteria were included for further analysis, among which 10 studies (22–31) were included for meta-analysis of HR for RFS, 3 studies (32–34) were included for meta-analysis of diagnostic accuracy for recurrence, and another 1 study (14) was included for systematic review of diagnostic accuracy for metastasis. Detailed selection process and reasons of exclusion were presented in Figure 1.

Study Characteristics
For the 10 included studies investigating RFS, a cumulative number of 1,093 SCC samples were analyzed. Tumor subsites were confined to head and neck regions, including the oral cavity, larynx, hypopharynx, and oropharynx. The duration of follow-up ranged from 28 months to more than 120 months, and all outcomes were evaluated by multivariate Cox regression models. Detailed characteristics of each study are presented in Table 1.

For the three included studies investigating diagnostic accuracy for recurrence, a total of 93 recurrence patients and 82 nonrecurrence controls were analyzed. Tumor subsites were confined to head and neck regions, including larynx and oral cavity. And the recurrence sites were not reported in most of the studies. Detailed characteristics of each study are presented in Table 2.

Similarly, for the included study investigating diagnostic accuracy for metastasis, a total of 25 metastasis patients and 23 nonmetastasis controls were analyzed. Tumor subsites were confined to head and neck regions. And the metastasis sites were reported to be the lymph node. Detailed characteristics of each study are presented in Table 2.

Synthesis of RFS and Subgroup Analysis
The pooled HR value for the outcomes of RFS in all HNSCC patients was 2.51 (95% CI: 2.13–2.96) (Figure 2). Poorer RFS correlated with upregulation of 14 microRNAs (miR-205-5p, miR-429, miR-21-3p, miR-331-3p, miR-200a-3p, miR-19a-3p, miR-21-5p, miR-151a-3p, miR-17-3p, miR-18b-5p, miR-324-5p, miR-96-5p, miR-141-5p, and miR-130a) and with downregulation of 7 microRNAs (miR-29c, miR-200b, miR-375, miR-422a, miR-15b-5p, miR-204, and miR-200c).

We further conducted a subgroup analysis based on anatomical subsites, and the results showed that pooled HR values for the outcomes of RFS were 2.02 (95% CI: 1.10–3.71) in oropharyngeal squamous cell carcinoma (OPSCC) patients and 2.12 (95% CI: 1.64–2.73) in oral squamous cell carcinoma (OSCC) patients (Figure 3). And in OPSCC patients, poorer RFS correlated with downregulation of miR-422a and miR-375. While in OSCC patients, poorer RFS correlated with upregulation of five microRNAs (miR-21-3p, miR-130b-3p, miR-96-5p, miR-141-3p, and miR-130a) and with downregulation of three microRNAs (miR-375, miR-204, and miR-200c) (Figure 3A). Meanwhile, we also conducted a subgroup analysis for individual microRNAs with more than two outcomes. And the expression levels of miR-21-3p, miR-96-5p, and miR-375 showed strong association with RFS, especially miR-21-3p, with a pooled HR value of 3.59 (95% CI: 1.91–6.76) (Figure 3B).

Taken together, our results showed that a panel of 21 microRNAs (miR-205-5p, miR-429, miR-21-3p, miR-331-3p, miR-200a-3p, miR-19a-3p, miR-21-5p, miR-151a-3p, miR-17-3p, miR-18b-5p, miR-324-5p, miR-96-5p, miR-141-3p, miR-130a, miR-29c, miR-200b, miR-375, miR-422a, miR-15b-5p, miR-204, and miR-200c) might have the potential to predict the prognosis of patients with HNSCCs, of which 2 microRNAs were associated with the prognosis of OPSCC patients, and 8 microRNAs were associated with the prognosis of OSCC patients.

Study Quality and Risk of Bias in Prognostic Studies
NOS scores of each prognostic study are listed in Table S1, of which eight studies (80%) were of “good” quality and deemed to have low risk of bias, while the other two studies (20%) were of “poor” quality and deemed to have high risk of bias mainly due to the lack of adjustment for important confounding variables. A Cohen’s kappa score of 0.76 revealed great agreement beyond chance between the two authors. Besides, no statistically significant heterogeneity ($P > 0.1$) and publication bias (Begg’s test: $P = 0.333$, Figure S1) was observed in the pooled analysis of RFS.

Pooled Diagnostic Accuracy of microRNAs for HNSCC Recurrence
The evaluation for the sensitivity and specificity of a panel of four microRNAs in diagnosing the recurrence of SCCs is illustrated in Figure 4A (miR-34c-5p, miR-186-5p, miR-3651,
and miR-494-5p). A sensitivity of 0.79 (95% CI: 0.72–0.85) and a specificity of 0.77 (95% CI: 0.68–0.83) were observed in patients with recurrence and nonrecurrence controls. The AUC was 0.85 (95% CI: 0.81–0.88), and the corresponding SROC curve is presented in Figure 4B.

Study Quality and Risk of Bias in Diagnostic Studies
As is shown in Figure S2, nearly all included diagnostic studies showed low risk of bias in patient selection, reference standard, and flow and timing; however, all of these three studies showed high risk of bias in index test mainly due to their retrospective nature, in which the index test results cannot be interpreted without knowledge of the results of the reference standard. Besides, the diagnostic thresholds in these studies were not confined and also not prespecified, which might cause some concerns on applicability. Meanwhile, no significant heterogeneity (P > 0.1) and publication bias (P = 0.53, Figure S3) was observed.

Overview ofDiagnostic Accuracy of microRNAs for LNM in HNSCC
Only one study reporting the diagnostic accuracy of four independent microRNAs for LNM in HNSCC met our eligibility criteria. However, given the high risk of bias for pooled analysis of four tests derived from the same study, meta-analysis was not conducted. de Carvalho et al. reported the diagnostic accuracy of miRNA-200a (sensitivity 0.76; specificity: 0.88; AUC: 0.92), miRNA-200c (sensitivity: 0.88; specificity: 1.00; AUC: 0.94), miRNA-203 (sensitivity: 1.00; specificity: 1.00; AUC: 1.00), and miRNA-205 (sensitivity: 1.00; specificity: 1.00; AUC: 1.00) in distinguishing 25 HNSCC patients with LNM from 23 HNSCC patients without LNM (14). All of these four microRNAs showed high diagnostic accuracy for detecting LNM in HNSCC patients; however, their performance was evaluated in the same cohort of which the sample size is not large enough. Thus, whether microRNAs have the potential for detecting LNM in HNSCC still needs to be validated by more studies with larger sample sizes.

DISCUSSION
In this review, we systematically analyzed 1,093 HNSCC samples from 10 studies (22–31) and identified a panel of 21 microRNAs related to poor RFS in HNSCC patients for the first time. Besides, we investigated the diagnostic accuracy of microRNAs for
Table 1 | Detailed characteristics and NOS scores of included studies investigating RFS.

| Author and Year | Country | MicroRNA | Tumor sites and sample size | Assay | Type of samples | Dysregulation | Cutoff value | Follow-up time | Survival analysis |
|-----------------|---------|----------|-----------------------------|-------|----------------|---------------|--------------|----------------|------------------|
| Ganci et al. (24) | Italy | miR-205-5p, miR-429, miR-21-3p, miR-200a-3p, miR-19a-3p, miR-21-5p, miR-151a-3p, miR-17-3p, miR-18b-5p, miR-324-5p, miR-96-5p | Oral cavity (n=73), larynx (n=29), hypopharynx (n=9) and oropharynx (n=10) | qPCR | Fresh frozen (tumor tissue) | Upregulation | According to special signal code | 73M | Multivariate |
| Ganci et al. (25) | Italy | miR-429, miR-21-5p, miR-96-5p, miR-21-3p | Head and neck (n=106) | qPCR | FFPE (peritumor tissue) | Upregulation | According to special signal code | 31M on average | Multivariate |
| Hudcova et al. (28) | Czech | miR-29c, miR-200b, miR-375 | Head and neck (n=42) | qPCR | Fresh frozen (tumor tissue) | Downregulation | Not reported | Unclear (more than 120M) | Multivariate |
| Bonnin et al. (23) | France | miR-422a | Oropharynx (n=75) | qPCR | Fresh frozen (tumor tissue) | Downregulation | Not reported | Unclear (more than 120M) | Multivariate |
| Ganci et al. (26) | Italy | miR-141-3p | Oral cavity (n=69) | qPCR | Fresh frozen (tumor tissue) | Downregulation | Not reported | Unclear (more than 120M) | Multivariate |
| Harris et al. (27) | America | miR-375 | Oral cavity (n=43) | qPCR | Fresh frozen (tumor tissue) | Downregulation | 25-percentile | Unclear (more than 60M) | Multivariate |
| Harris et al. (27) | America | miR-375 | Oropharynx (n=37) | qPCR | Fresh frozen (tumor tissue) | Downregulation | 25-percentile | Unclear (more than 60M) | Multivariate |
| Harris et al. (27) | America | miR-375 | Larynx (n=43) | qPCR | Fresh frozen (tumor tissue) | Downregulation | 25-percentile | Unclear (more than 60M) | Multivariate |
| Ahmad et al. (22) | Czech | miR-15b-5p | Oral cavity (n=6), hypopharynx (n=6), larynx (n=8), oropharynx (n=23) | qPCR | FFPE (tumor tissue) | Downregulation | Not reported | Unclear (more than 60M) | Multivariate |
| He et al. (29) | China | miR-130a | Oral cavity (n=92) | qPCR | Fresh frozen (plasma) | Upregulation | Median relative expression level | 36M | Multivariate |
| Rajthala et al. (30) | Norway | miRNA-204 | Oral cavity (n=158) | qPCR | FFPE (tumor tissue) | Downregulation | Not reported | 8.6Y on average | Multivariate |
| Song et al. (31) | China | miR-200c | Oral cavity (n=204) | qPCR | Fresh frozen (tumor tissue) | Downregulation | Median relative expression level | 36M | Multivariate |

Table 2 | Detailed characteristics of included studies investigating diagnostic values of microRNAs for recurrence and LNM.

| Author and Year | Country | MicroRNA | Tumor sites and sample size | Assay | Type of samples | Number of samples | Metastasis/Recurrence sites |
|-----------------|---------|----------|-----------------------------|-------|----------------|-------------------|-----------------------------|
| de Carvalho et al. (14) | Brazil | miR-200a, miR-200c, miR-203, miR-205 | Head and neck (n=48) | qPCR | FFPE (lymph node) | 25/23 | Lymph node (metastasis) |
| Re et al. (32) | Italy | miR-34c-5p | Larynx (n=90) | qPCR | FFPE (tumor tissue) | 49/41 | Not reported (recurrence) |
| Re et al. (33) | Italy | miR-34c-5p | Larynx (n=43) | qPCR | FFPE (tumor tissue) | 23/20 | Not reported (recurrence) |
| Ries et al. (34) | Austria | miR-186-5p, miR-3851, miR-494-5p | Oral cavity (n=42) | qPCR | Fresh frozen (whole blood) | 21/21 | Not reported (recurrence) |
recurrence (by analyzing 93 recurrence patients and 82 nonrecurrence controls from 3 studies) and LNM (by presenting an overview of 25 metastasis patients and 23 nonmetastasis controls from another study). We observed relatively high diagnostic accuracy of microRNAs in diagnosing recurrence and LNM for HNSCCs, which have the potential to assist imaging modalities and histopathology biopsy in the diagnosis and prognosis for HNSCC patients.

In the current study, we specifically took recurrence and metastasis as the outcomes. Our results showed that a panel of 21 microRNAs might be suitable biomarkers for predicting the recurrence of HNSCCs (pooled HR: 2.51, 95% CI: 2.13–2.96, I² = 0), among which poor RFS correlated with upregulation of 14 microRNAs (miR-205-5p, miR-429, miR-21-3p, miR-331-3p, miR-200a-3p, miR-200c-3p, miR-200b-3p, miR-19a-3p, miR-21-5p, miR-151a-3p, miR-200b-5p, miR-151b-5p, and miR-21-5p).

FIGURE 2 | Forest plot for the association between microRNA expression and recurrence-free survival (RFS).

FIGURE 3 | (A) Forest plot for subgroup analysis of the association between microRNA expression and recurrence-free survival (RFS) based on anatomical subsites. (B) Forest plot for subgroup analysis of the association between microRNA expression and recurrence-free survival (RFS) based on microRNAs (only individual microRNAs with more than two outcomes were presented).
miR-130a) or with downregulation of 7 microRNAs (miR-29c, miR-200b, miR-375, miR-422a, miR-15b-5p, miR-204, and miR-200c). Besides, subgroup analyses revealed similar trends in OSCC and OPSCC patients as well as identified miR-21-3p, miR-96-5p, and miR-375, which showed strong association with RFS. Our quality assessments showed that 80% of the included studies investigating RFS were of good quality, and the meta-analysis was of low risk of bias, which reinforced the reliability of our results. Meanwhile, the diagnostic accuracy of microRNAs in HNSCC recurrence was decent (sensitivity: 0.79, 95% CI: 0.72–0.85; specificity: 0.77, 95% CI: 0.68–0.83; AUC: 0.85, 95% CI: 0.81–0.88), together with a low rate of heterogeneity and low risk of publication bias. Additionally, the diagnostic accuracy of microRNAs in LNM of HNSCC reported by de Carvalho et al. was relatively high but needs further validation.

We further summarized these analyzed microRNAs and explored their well-known biological functions related to tumor malignant behaviors in Table S2. As expected, the downregulation of microRNAs, which had been previously reported to be related to tumor suppressing functions, including inhibiting tumor cell proliferation, migration, and invasion (18, 35–61), was associated with poorer RFS in our study. Similarly, the upregulation of microRNAs, which had been previously reported to function as enhancers of tumor malignant behaviors (62–83), were associated with poorer RFS. Besides, the modulation of epithelial to mesenchymal transition (EMT), an essential early step of tumor metastasis, was identified as the most commonly reported mechanism, through which those microRNAs regulate malignant behaviors of other types of tumor. Meanwhile, surprisingly, we found five members of the microRNA-200 family (miR-200a, miR-200b, miR-200c, miR-429, and miR-141), which are known for their regulatory function on EMT, and their combination might act as a strong prognosis predictor (Figure S3) (39, 84–88). Thus, we hypothesized that the modulation of EMT and subsequent cell migration and invasion might also act as the key pathophysiological mechanisms of the interplay between microRNAs and HNSCC, which still needs to be further confirmed by mechanistical studies.

There were some limitations in this study. First, given the fact that most of the included studies performed their analyses in HNSCC samples with mixed subsites, which cannot be strictly separated, therefore subgroup analysis could only be available in OSCC and OPSCC patients. And consequently, whether our conclusions can be generalized to SCC derived from other subsites remained to be verified by further studies with larger sample sizes and a wider spectrum of HNSCC subsites. Second, it is also a pity that most of these included studies have not performed subgroup analyses based on HPV status; thus, we were not able to properly investigate the influence of the HPV status. However, most of these included studies have adjusted the HPV status in their multivariate analysis, which might reduce its influence to some extent. Third, the outcomes of four independent microRNAs for LNM in HNSCC were retrieved from the same study. Thus, pooled analysis was not conducted due to the potential high risk of bias. And the reported high diagnostic accuracy still needs to be further validated. Additionally, our results should be explained cautiously since our panels have significance when these microRNAs are taken as a whole, not individually.

**DATA AVAILABILITY STATEMENT**

The datasets generated for this study are available on request to the corresponding authors.
AUTHOR CONTRIBUTIONS

JR and YZ contributed to the study conception and design. Material preparation was performed by QL and WP, data collection was performed by YR, and analysis was performed by KQ, YS, YR, and DC. The first draft of the manuscript was written by KQ and YS, and all authors commented on previous versions of the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by West China Hospital, Sichuan University (YZ, grant # 2019HXFH003, grant # ZYJC21027); Chengdu Science and Technology Bureau (JR, grant # 20GJHZ0193); Sichuan University (YZ, grant # 20ZDYF3010, RJJ, grant # 2019HXBH079, #2020SCU12049); The Science and Technology Department of Sichuan Province (YZ, grant # 2020YFH0090, RJJ, grant#2020YSF0111); The Health Department of Sichuan Province (JR, grant # 20P030); China Postdoctoral Science Foundation (JR, grant # 2020M673250); The Foundation of National Clinical Research Center for Geriatrics (SH, grant # Z20201013); and National Natural Youth Science Foundation of China (JR, grant # 82002868).

REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global Cancer Statistics. CA Cancer J Clin (2015) 65(2):87–108. doi: 10.3322/caac.21262
2. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends–An Update. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Research cnsponed by Am Soc Prev Oncol (2016) 25 (1):16–27. doi: 10.1185/1055-9965.EPI-15-0578
3. Sanchez-Danes A, Blanpain C. Deciphering the Cells of Origin of Squamous Cell Carcinomas. Nat Rev Cancer (2018) 18(9):549–61. doi: 10.1038/s41568-018-0024-5
4. Alsahafi E, Begg K, Amelio I, Rauf N, Lucarelli P, Sauter T, et al. Clinical Update on Head and Neck Cancer: Molecular Biology and Ongoing Challenges. Cell Death Dis (2019) 10(8):540. doi: 10.1038/s41419-017-1699-9
5. Dotto GP, Rustgi AK. Squamous Cell Cancers: A Unified Perspective on Biology and Genetics. Cancer Cell (2016) 29(5):622–37. doi: 10.1016/j.ccell.2016.04.004
6. Mathelier A, Shi W, Wasserman WW. Identification of Altered Cis-Regulatory Elements in Human Disease. Trends Genet (2015) 31(2):67–76. doi: 10.1016/j.tig.2014.12.003
7. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and Neck Cancer. Lancet (2008) 371(9625):1695–709. doi: 10.1016/S0140-6736(08)60728-X
8. Svidere PF, Blasco MA, Raza SN, Shkoukani M, Sukari A, Yoo GH, et al. Head and Neck Cancer. Otolaryngol Head Neck Surg (2017) 156(1):10–3. doi: 10.1177/0194599816674672
9. Huang SH, O’Sullivan B. Overview of the 8th Edition TNM Classification for Head and Neck Cancer. Curr Treat Options Oncol (2017) 18(7):40. doi: 10.1007/s11972-017-0484-y
10. Denaro N, Russi EG, Merlano MC. Pros and Cons of the New Edition of TNM Classifications. J Clin Oncol (2018) 36(4):202–10. doi: 10.1159/000490415
11. Jonas S, Izaurralde E. Towards a Molecular Understanding of microRNA-Mediated Gene Silencing. Nat Rev Genet (2015) 16(7):421–33. doi: 10.1038/nrg3965
12. Benacchi N, Woodhouse S, Goldie SJ, Mishra A, Quist SR, Watt FM. Rewiring of an Epithelial Differentiation Factor, miR-203, to Inhibit Human Squamous Cell Carcinoma Metastasis. Cell Rep (2014) 9(1):104–17. doi: 10.1016/j.celrep.2014.08.062
13. Chang WM, Lin YF, Su CY, Peng HY, Chang YC, Lai TC, et al. Dysregulation of RUNX2/Activin-A Axis Upon miR-376c Downregulation Promotes Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma. Cancer Res (2016) 76(24):7140–50. doi: 10.1158/0008-5472.CAN-16-1188
14. de Carvalho AC, Scapulatempo-Neto C, Maia DC, Evangelista AF, Morini MA, Carvalho AL, et al. Accuracy of microRNAs as Markers for the Detection of Neck Lymph Node Metastases in Patients with Head and Neck Squamous Cell Carcinoma. BMC Med (2015) 13:108. doi: 10.1186/s12916-015-0350-3
15. Hiyoishi Y, Kamohara H, Karashima R, Sato N, Imamura Y, Nagai Y, et al. MicroRNA-21 Regulates the Proliferation and Invasion in Esophageal Squamous Cell Carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res (2009) 15(6):1915–22. doi: 10.1158/1078-0432.CCR-08-2545
16. Huang WC, Chan SH, Jang TH, Jiang JW, Ko YC, Yen TC, et al. miRNA-491-5p and GTF1 Serve as Modulators and Biomarkers for Oral Squamous Cell Carcinoma Invasion and Metastasis. Cancer Res (2014) 74(3):751–64. doi: 10.1158/0008-5472.CAN-13-1297
17. Huang WC, Jang TH, Tung SL, Yen TC, Chan SH, Wang LH. A Novel miR-365-3p/EHF/Keratin 16 Axis Promotes Oral Squamous Cell Carcinoma Metastasis, Cancer Stemness and Drug Resistance via Enhancing Beta5-Integrin/C-Met Signaling Pathway. J Exp Clin Cancer Res CR (2019) 38(1):89. doi: 10.1186/s13046-019-1091-5
18. Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Yi Y, et al. MicroRNA-375 Inhibits Tumour Growth and Metastasis in Oesophageal Squamous Cell Carcinoma Through Repressing Insulin-Like Growth Factor 1 Receptor. Gut (2012) 61(1):33–42. doi: 10.1136/gutjnl-2011-300718
19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. J Clin Epidemiol (2009) 62(10):e1–e43. doi: 10.1016/j.cej.2009.06.006
20. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Ann Intern Med (2011) 155(8):529–36. doi: 10.7326/0003-4819-155-8-201110180-00009
21. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical Methods for Incorporating Summary Time-to-Event Data Into Meta-Analysis. Trials (2007) 8:16. doi: 10.1186/1746-6013-8-16
22. Ahmad P, Sana J, Slavik M, Gurin D, Radova L, Gablo NA, et al. MicroRNA-15b-5p Predicts Locoregional Relapse in Head and Neck Carcinoma Patients Treated With Intensity-Modulated Radiotherapy. Cancer Genomics Proteomics (2019) 16(2):139–46. doi: 10.21873/cgp.20119
23. Bonnin N, Armandy E, Carras J, Ferrandon S, Battiston-Montagne P, Aubry M, et al. MiR-422a Promotes Loco-Regional Recurrence by Targeting NT5E/CD73 in Head and Neck Squamous Cell Carcinoma. Oncotarget (2016) 7(28):44023–38. doi: 10.18632/oncotarget.9829
24. Ganci F, Sacconi A, Bossel Ben-Moshe N, Manciocco V, Sperduti I, Strigari L, et al. Expression of TP53 Mutation-Associated microRNAs Predicts Clinical Outcome in Head and Neck Squamous Cell Carcinoma Patients. Ann Oncol Off J Eur Soc Med Oncol (2013) 24(12):3082–8. doi: 10.1093/annonc/mdt380
25. Ganci F, Sacconi A, Manciocco V, Covello R, Benvolio M, Rolfo F, et al. Altered Peritumoral microRNA Expression Predicts Head and Neck Cancer Patients With a High Risk of Recurrence. Modern Pathol an Off J United States Can Acad Pathol Inc (2017) 30(10):1387–401. doi: 10.1038/mpatmodpathol.2017.62
26. Ganci F, Sacconi A, Manciocco V, Sperduti I, Battaglia P, Covello R, et al. MicroRNA Expression as Predictor of Local Recurrence Risk in Oral Squamous Cell Carcinoma. Head Neck (2016) 38 Suppl 1:E189–97. doi: 10.1002/hed.23969

27. Harris T, Jimenez L, Kawachi N, Fan J-B, Chen J, Belbin T, et al. Low-Level Expression of miR-375 Correlates With Poor Outcome and Metastasis While Altering the Invasive Properties of Head and Neck Squamous Cell Carcinomas. *Am J Pathol* (2012) 180(3):917–28. doi: 10.1016/j.ajpath.2011.12.004

28. Hudcova K, Raudenska M, Gumulec J, Binkova H, Horakova Z, Kostrica R, et al. Expression Profiles of miR-29c, miR-200b and miR-375 in Tumour and Tumour-Adjacent Tissues of Head and Neck Cancers. *Tumour Biol* Int Soc Oncodevelopmental Biol Med (2016) 37(9):12627–33. doi: 10.1007/s13277-016-5417-2

29. He T, Guo X, Li X, Liao C, Wang X, He K. Plasma-Derived Exosomal microRNA-130a Serves as a Noninvasive Biomarker for Diagnosis and Prognosis of Oral Squamous Cell Carcinoma. *J Oncol* (2021) 2021:5547911. doi: 10.1155/2021/5547911

30. Rajthala S, Dongre H, Parajuli H, Min A, Nginamau ES, Kvalheim A, et al. Combined In Situ Hybridization and Immunohistochemistry on Archival Tissues Reveals Strunal microRNA-204 as a Prognostic Biomarker for Oral Squamous Cell Carcinoma. *Cancers (Basel)* (2021) 13(6):1370. doi: 10.3390/cancers13061370

31. Song J, Zhang N, Cao L, Xiao D, Ye X, Luo E, et al. Down-Regulation of miR-200c Associates With Poor Prognosis of Oral Squamous Cell Carcinoma. *Int J Clin Oncol* (2020) 25(6):1072–8. doi: 10.1007/s10147-020-01649-2

32. Re M, Ceka A, Rubini C, Ferrante L, Zizzi A, Gioacchini FM, et al. MicroRNA-34c-5p in Laryngeal Squamous Cell Carcinoma. *Ann Oncol* (2019) 30:427. doi: 10.1093/annonc/mdz042

33. He T, Guo X, Li X, Liao C, Wang X, He K. Plasma-Derived Exosomal microRNA-130a Serves as a Noninvasive Biomarker for Diagnosis and Prognosis of Oral Squamous Cell Carcinoma. *J Oncol* (2021) 2021:5547911. doi: 10.1155/2021/5547911

34. Liu N, Tang L, Tang C, Na M, Ma W, Jiang Z, Gu Y, et al. miR-422a Inhibits Glioma Cell Proliferation and Invasion, and Enhances Chemosensitivity in Osteosarcoma Cells. *Oncol Rep* (2016) 36(6):3371–8. doi: 10.22066/2016.5182

35. Yang S, Yang R, Lin R, Si L. MicroRNA-375 Inhibits the Growth, Drug Sensitivity and Metastasis of Human Ovarian Cancer Cells by Targeting PXA2. *J Iuon* (2019) 24(4):2341–6.

36. Cao ZH, Cheng JL, Zhang Y, Bo CX, Li YL. MicroRNA–375 Inhibits Oral Squamous Cell Carcinoma Cell Migration and Invasion by Targeting Platelet–Derived Growth Factor-a. *Mol Med Rep* (2017) 15(2):922–8. doi: 10.3892/mmr.2016.6505

37. Cui F, Wang S, Lao I, Zhou C, Kong H, Bayasi N, et al. miR-375 Inhibits the Invasion and Metastasis of Colorectal Cancer via Targeting SP1 and Regulating EMT-Associated Genes. *Oncol Rep* (2016) 36(1):847–93. doi: 10.3892/or.2016.4834

38. Jimenez L, Sharma VP, Condeels J, Harris T, Ow TJ, Prystowsky MB, et al. MicroRNA-375 Suppresses Extracellular Matrix Degradation and Invapodol Activity in Head and Neck Squamous Cell Carcinoma. *Arch Pathol Lab Med* (2015) 139(11):1349–61. doi: 10.5888/apra.2014.0471-0A

39. Wang F, Li Y, Zhou J, Xu J, Feng C, Ye F, et al. miR-375 is Down-Regulated in Squamous Cervical Cancer and Inhibits Cell Migration and Invasion via Transcription Factor SP1. *Am J Pathol* (2011) 179(5):2580–8. doi: 10.1016/j.ajpath.2011.07.037

40. Wang H, Zhu Y, Zhao M, Wu C, Zhang P, Tang L, et al. MicroRNA-422a Functions as a Tumor Suppressor in Glioma by Regulating the Wnt/β-Catenin Signaling Pathway via RP2N2. *Oncol Rep* (2020) 44(5):2108–20. doi: 10.3892/or.2020.7741

41. Wang H, Tang C, Na M, Ma W, Jiang Z, Gu Y, et al. miR-422a Inhibits Glioma Proliferation and Invasion by Targeting IGFI and IGFR1. *Oncol Rep* (2017) 27(2):187–94. doi: 10.3727/096502216x147327721508389

42. Zhang J, Yang Y, Yang T, Yuan S, Wang R, Pan Z, et al. Double-Negative Feedback Loop Between microRNA-422a and Forkhead Box (FOX)G1/FOX1-Regulates Hepatocellular Carcinoma Tumor Growth and Metastasis. *Hepatology* (2015) 61(2):561–73. doi: 10.1002/hep.27491

43. Chava S, Reynolds CP, Pathania AS, Poluektova LY, Coulter DW, et al. miR-15a-5p, miR-15b-5p, and miR-16-5p Inhibit Tumor Progression by Directly Targeting MYCN in Neuroblastoma. *Mol Oncol* (2020) 14(1):180–96. doi: 10.1002/1878-0261.12588

44. Chung TK, Lau TS, Cheung TH, Yim SF, Lo KW, Siu NS, et al. Dysregulation of microRNA-204 Mediates Migration and Invasion of Endometrial Cancer by Regulating FOXC1. *Int J Cancer* (2012) 130(5):1036–45. doi: 10.1002/ijc.26600

45. Fan X, Fang X, Liu G, Xiong Q, Li Z, Zhou W. MicroRNA-204 Inhibits the Proliferation and Metastasis of Breast Cancer Cells by Targeting PI3K/AKT Pathway. *J buon* (2019) 24(3):1054–9.

46. Hu WB, Wang L, Huang XR, Li F. MicroRNA-204 Targets SOX4 to Inhibit Metastasis of Lung Adenocarcinoma. *Eur Rev Med Pharmacol Sci* (2019) 23(4):1533–62. doi: 10.26355/eurrev_201902_17114

47. Shi L, Zhang B, Sun X, Lu S, Liu Z, Liu Y, et al. Micro-R-204 Inhibits Human NSCLC Metastasis Through Suppression of NAA11K. *Br J Cancer* (2014) 111(12):2316–27. doi: 10.1038/bjc.2014.580

48. Yang S, Chen B, Zhang B, Li C, Qiu Y, Yang H, et al. Micro-R-204-Promotes Apoptosis and Inhibits Migration of Gastric Cancer Cells by Targeting HER-2. *Mol Med Rep* (2020) 22(4):2645–54. doi: 10.3892/mmr.2020.11367

49. Yu Y, Wang Y, Xiao C, Cheng W, Hu L, Yao W, et al. Micro-R-204 Inhibits Hepatocellular Cancer Drug Resistance and Metastasis Through Targeting NAA10K. *Biochem Cell Biol* (2019) 97(5):563–70. doi: 10.1139/bcb-2018-0354

50. Zhang B, Cui H, Sun Y, Wang Y, Jia Q, Li J, et al. Up-Regulation of miR-204 Inhibits Proliferation, Invasion and Apoptosis of Gaibladder Cancer Cells by Targeting Notch2. *Aging (Albany NY)* (2021) 13(2):2941–58. doi: 10.16862/aging.20444

51. Cao W, Zhao Y, Wang L, Huang X. Circ0001429 Regulates Progression of Bladder Cancer Through Binding miR-205-5p and Promoting VEGFA Expression. *Cancer biomark* (2019) 25(1):101–13. doi: 10.3323/crm.182380
63. De Cola A, Lamolinar A, Lanuti P, Rosci C, Iezzi M, Marchisio M, et al. Mir-205-5p Inhibition by Locked Nucleic Acids Impairs Metastatic Potential of Breast Cancer Cells. CellBioRNA (2019) 15:1(8):821. doi: 10.1038/s41419-018-0854-9

64. Lang Y, Xu S, Ma J, Wu J, Jin S, Cao S, et al. MicroRNA-429 Induces Tumorigenesis of Human Non-Small Cell Lung Cancer Cells and Targets Multiple Tumor Suppressor Genes. Biochem Biophys Res Commun (2014) 450 (1):154–9. doi: 10.1016/j.bbrc.2014.05.084

65. Dobersstein K, Bretz NP, Schirmer U, Fiegl H, Blaheta R, Breunig C, et al. miR-21-3p is a Positive Regulator of L1CAM in Several Human Carcinomas. Cancer Lett (2014) 354(2):455–66. doi: 10.1016/j.canlet.2014.08.020

66. Tseng HH, Tseng YK, You JJ, Kang BH, Wang TH, Yang CM, et al. Next-Generation Sequencing for microRNA Profiling: MicroRNA-21-3p Promotes Oral Cancer Metastasis. Anticancer Res (2017) 37(3):1059–66. doi: 10.21873/ anticancer.11417

67. Chang RM, Yang H, Fang F, Xu JF, Yang LY. MicroRNA-331-3p Promotes Proliferation and Metastasis of Hepatocellular Carcinoma by Targeting PH Domain and Leucine-Rich Repeat Protein Phosphatase. Hepatology (2014) 60 (4):1251–63. doi: 10.1002/hep.27221

68. Chen HH, Zong J, Wang SJ. LncRNA GAPLINC Promotes the Growth and Metastasis of Glioblastoma by Spawning miR-331-3p. Eur Rev Med Pharmacol Sci (2019) 23(1):262–70. doi: 10.26355/eurrev_201901_16772

69. Sarkar A, Rahaman A, Biswas I, Mukherjee G, Chatterjee S, Bhattacharjee S, et al. Tgfβ Mediated LINCO273 Upregulation Sponges Mir200a-3p and Promotes Invasion and Metastasis by Activating ZEB1. J Cell Physiol (2020) 235(10):7159–72. doi: 10.1002/jcp.29614

70. Feng S, Zhu X, Fan B, Xie D, Li T, Zhang X. Mir–19a–3p Targets PMEPA1 and Induces Prostate Cancer Cell Proliferation, Migration and Invasion. Mol Med Rep (2016) 13(5):4030–8. doi: 10.3892/mmr.2016.5033

71. Jiang XM, Yu NX, Liu TT, Zou HR, Shi X, Bilegsaikhan E, et al. microRNA-19a-3p Promotes Tumor Metastasis and Chemoresistance Through the PTEN/Akt Pathway in Hepatocellular Carcinoma. BioMed Pharmacother (2018) 105:1147–54. doi: 10.1016/j.biopharm.2018.06.097

72. Li Q, Li B, Li Q, Wei S, He Z, Huang X, et al. Exosomal miR-21-5p-derived from Gastrointestinal Cancer Promotes Peritoneal Metastasis via Mesothelial-to-Mesenchymal Transition. Cell Death Dis (2018) 9(9):854. doi: 10.1038/s41419-018-0928-8

73. Zhang R, Xia T. Long Non-Coding RNA XIST Regulates PDCC4 Expression by Interacting With miR-21-5p and Inhibits Osteosarcoma Cell Growth and Metastasis. Int J Oncol (2017) 51(5):1460–70. doi: 10.3822/ijo.2017.4127

74. Zhu Y, Bo H, Chen Z, Li J, He D, Xiao M, et al. LINCO0968 can Inhibit the Progression of Lung Adenocarcinoma Through the miR-21-5p/SMAD7 Signal Axis. Aging (Albany NY) (2020) 12(11):21904–22. doi: 10.18632/aging.104011

75. Liu H, Cheng Y, Xu Y, Xu H, Liu Z, Fan J, et al. The Inhibition of Tumor Protein P53 by microRNA-151a-3p Induces Cell Proliferation, Migration and Invasion in Nasopharyngeal Carcinoma Cells. BioMed Res Int (2019) 39(10):1679–92. doi: 10.1155/2019/1525769

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Qiu et al. MicroRNAs Predict Cancer Clinical Behaviors. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.